What's Happening?
Beren Therapeutics announced that the FDA has extended the review period for its New Drug Application (NDA) for adrabetadex, a treatment for infantile-onset Niemann-Pick disease, type C (I-NPC). The new target action date is set for November 17, 2026.
This extension follows Beren's response to an FDA request for additional data, classified as a Major Amendment. Adrabetadex has received Priority Review, Orphan Drug Designation, and Breakthrough Therapy Designation from the FDA.
Why It's Important?
The extension of the review period highlights the complexity and challenges in developing treatments for rare diseases like I-NPC, which affects cholesterol trafficking in cells. Adrabetadex's potential approval could provide a much-needed therapy for a condition with limited treatment options, impacting the lives of affected children and their families. The drug's development underscores the importance of regulatory pathways like Priority Review and Orphan Drug Designation in facilitating access to innovative treatments for rare diseases.
What's Next?
Beren Therapeutics will continue to work closely with the FDA to address any remaining questions and ensure a thorough review process. The company is also providing adrabetadex to eligible patients through an Expanded Access Program, which may help gather additional data on the drug's safety and efficacy. The outcome of the FDA's review will be crucial for Beren's future plans and the potential commercialization of adrabetadex.
